cc312
mAbexperimentalTri-specific
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 7, 2023 (NCT06037018)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anemia, Hemolytic, Autoimmune · Early Phase 1
- Arthritis, Rheumatoid · Early Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lupus Erythematosus, Systemic · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Myositis · Early Phase 1
- Sclerosis · Early Phase 1
- Thrombocytopenia · Early Phase 1
Mechanism of action
CD3E activator
- B-lymphocyte antigen CD19BINDING AGENT
CD19 binding agent
CD28 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Tri-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07193810 | Early Phase 1 (Phase 1) | Sep 30, 2025 | CytoCares Inc |
| NCT07177911 | Phase 1 | Sep 11, 2025 | CytoCares Inc |
| NCT06888960 | Early Phase 1 (Phase 1) | Nov 8, 2024 | CytoCares Inc |
| NCT06037018 | Phase 1 | Aug 7, 2023 | China Academy of Chinese Medical Sciences, CytoCares Inc |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CytoCares Inc | For profit | 4 | 4 | 1 | 2023 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1